Eliem Therapeutics Current Valuation vs. Total Debt
| ELYMDelisted Stock | USD 3.04 0.19 5.88% |
For Eliem Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Eliem Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Eliem Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Eliem Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Eliem Therapeutics over time as well as its relative position and ranking within its peers.
Eliem |
Eliem Therapeutics Total Debt vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Eliem Therapeutics's current stock value. Our valuation model uses many indicators to compare Eliem Therapeutics value to that of its competitors to determine the firm's financial worth. Eliem Therapeutics is rated below average in current valuation category among its peers. It is rated below average in total debt category among its peers making up about 0.01 of Total Debt per Current Valuation. The ratio of Current Valuation to Total Debt for Eliem Therapeutics is roughly 68.31 . As of the 2nd of December 2024, Total Debt To Capitalization is likely to grow to 0. Comparative valuation analysis is a catch-all technique that is used if you cannot value Eliem Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Eliem Current Valuation vs. Competition
Eliem Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 1.24 Billion. Eliem Therapeutics claims roughly 23.84 Million in current valuation contributing just under 2% to equities under Health Care industry.
Eliem Total Debt vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Eliem Therapeutics |
| = | 23.84 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Eliem Therapeutics |
| = | 349 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Eliem Total Debt vs Competition
Eliem Therapeutics is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 69.62 Million. Eliem Therapeutics adds roughly 349,000 in total debt claiming only tiny portion of equities under Health Care industry.
Eliem Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Eliem Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Eliem Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Eliem Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Eliem Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -2 K | -2.1 K | |
| Operating Income | -21.5 M | -22.5 M | |
| Net Loss | -39.2 M | -41.2 M | |
| Income Before Tax | -35.1 M | -36.9 M | |
| Total Other Income Expense Net | -13.7 M | -13 M | |
| Net Loss | -40.7 M | -42.8 M | |
| Net Loss | -35.1 M | -36.9 M | |
| Income Tax Expense | -21.5 K | -22.5 K | |
| Non Operating Income Net Other | -125.3 K | -131.6 K | |
| Net Interest Income | 4.6 M | 3.3 M | |
| Interest Income | 4.6 M | 3.3 M | |
| Change To Netincome | 8.5 M | 6.3 M | |
| Net Loss | (1.30) | (1.37) | |
| Income Quality | 0.59 | 0.79 | |
| Net Income Per E B T | 0.90 | 0.57 |
Eliem Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Eliem Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Eliem Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Eliem Therapeutics' important profitability drivers and their relationship over time.
Use Eliem Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eliem Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eliem Therapeutics will appreciate offsetting losses from the drop in the long position's value.Eliem Therapeutics Pair Trading
Eliem Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Eliem Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eliem Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eliem Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eliem Therapeutics to buy it.
The correlation of Eliem Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eliem Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eliem Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eliem Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Eliem Therapeutics position
In addition to having Eliem Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Baby Boomer Prospects Thematic Idea Now
Baby Boomer Prospects
Equities with large market capitalization that account for significant contribution to overall economic growth especially within dividend-paying instruments and stocks from healthcare and financial sectors. The Baby Boomer Prospects theme has 99 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Baby Boomer Prospects Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |